Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 1
2009 3
2010 1
2011 3
2012 4
2013 2
2014 4
2015 3
2016 8
2017 6
2018 8
2019 9
2020 16
2021 8
2022 9
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
Koresawa-Shimizu R, Suzuki R, Uehara Y, Hiramoto N, Sawa M, Fukuda T, Kataoka K, Kanda Y, Oyake T, Kubota Y, Uchida N, Yano S, Kobayashi H, Tanaka J, Atsuta Y, Kondo E. Koresawa-Shimizu R, et al. Among authors: kubota y. Bone Marrow Transplant. 2024 Jan;59(1):125-127. doi: 10.1038/s41409-023-02118-w. Epub 2023 Oct 7. Bone Marrow Transplant. 2024. PMID: 37805626 No abstract available.
[De novo blast phase of chronic myeloid leukemia with 3q26 abnormality diagnosed by cytogenetic analysis of extramedullary lesion].
Matsunaga T, Naganuma K, Tabayashi T, Kawada T, Sakata N, Takahashi Y, Kimura Y, Anan T, Mitsuhashi T, Kubota Y, Sawada K, Yamashita T, Momose S, Higashi M, Tamaru JI, Kizaki M. Matsunaga T, et al. Among authors: kubota y. Rinsho Ketsueki. 2022;63(12):1643-1647. doi: 10.11406/rinketsu.63.1643. Rinsho Ketsueki. 2022. PMID: 36653137 Japanese.
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H. Wakita S, et al. Among authors: kubota y. Cancer Sci. 2023 Apr;114(4):1297-1308. doi: 10.1111/cas.15720. Epub 2023 Jan 27. Cancer Sci. 2023. PMID: 36610002 Free PMC article.
[Acute lymphoblastic leukemia with "masked" Philadelphia chromosome].
Naganuma K, Tabayashi T, Kawada T, Sakata N, Takahashi Y, Kimura Y, Anan T, Mitsuhashi T, Kubota Y, Kizaki M. Naganuma K, et al. Among authors: kubota y. Rinsho Ketsueki. 2022;63(11):1525-1529. doi: 10.11406/rinketsu.63.1525. Rinsho Ketsueki. 2022. PMID: 36476792 Japanese.
Diffuse Large B-cell Lymphoma Involving an Abundant Infiltration of T Follicular Helper Cells.
Ishii K, Kamachi K, Okamoto S, Katsuya H, Fujita M, Nagaie T, Nishioka A, Yoshimura M, Ureshino H, Kubota Y, Ando T, Watanabe T, Takeuchi M, Kai K, Ohshima K, Kimura S. Ishii K, et al. Among authors: kubota y. Intern Med. 2023 May 1;62(9):1335-1340. doi: 10.2169/internalmedicine.0521-22. Epub 2022 Sep 21. Intern Med. 2023. PMID: 36130892 Free PMC article.
Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320.
Arai K, Sakaguchi M, Yui S, Kitano T, Miyata M, Yogosawa M, Nakayama K, Tajika K, Usuki K, Kuroda J, Uoshima N, Kobayashi Y, Uchiyama H, Kubota Y, Kimura S, Mori S, Hirai M, Wakita S, Yamaguchi H. Arai K, et al. Among authors: kubota y. Int J Lab Hematol. 2022 Dec;44(6):1102-1110. doi: 10.1111/ijlh.13938. Epub 2022 Aug 30. Int J Lab Hematol. 2022. PMID: 36039795
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. Marumo A, et al. Among authors: kubota y. Int J Hematol. 2022 Aug;116(2):199-214. doi: 10.1007/s12185-022-03328-6. Epub 2022 Apr 4. Int J Hematol. 2022. PMID: 35377134
73 results